Iscar for Supplemental Care in Stage IV Lung Cancer

Lung Cancer Clinical Trial

Official title:

Iscar for Supplemental Care in Stage IV Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00079794
• Other study ID #: R21AT001020-01
• Secondary ID: Rosenzweig
• Status: Completed
• Phase: Phase 2
• First received: March 15, 2004
• Last updated: January 23, 2008
• Start date: September 2001
• Est. completion date: February 2004

Study information

• Verified date: January 2008
• Source: National Center for Complementary and Integrative Health (NCCIH)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

Description:

See Brief Summary

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: February 2004
• Est. primary completion date: February 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stage IV NSCLC patients who receive standard chemotherapy

Exclusion criteria:

• Known allergy to Viscum Album L.

• Concomitant use of other mistletoe products

• Concomitant use of mushroom glucan and proteoglycan extracts

• Concomitant use of thymus extract products

• Inability to self-report quality of life utilizing assessment tools

• Ongoing steroid or ACTH therapy

• Co-morbid immunocompromised state

• Pregnancy

• Participation in other clinical trials

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Iscar

• mistletoe

Locations

Country	Name	City	State
United States	Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States,